When Does Liraglutide's Main Patent Expire?
Liraglutide, sold as Victoza for diabetes and Saxenda for weight loss, has key U.S. patents expiring in June 2023 (Victoza) and ongoing protections for Saxenda until 2030 due to formulation and method-of-use claims.[1] Post-2023 expiry for Victoza, generics became eligible, but no FDA-approved generic liraglutide versions exist as of late 2024. Novo Nordisk holds pediatric exclusivity until January 2024 and faces ongoing litigation delaying ANDA approvals.
Why No Generics Yet Despite Expiry?
Challenges include complex manufacturing of liraglutide, a peptide requiring specific folding and stability, which deters generic makers. FDA requires proving bioequivalence, and Novo Nordisk has sued challengers like Mylan and Teva over secondary patents (e.g., device and injection patents expiring 2026-2032).[2] Paragraph IV challenges under Hatch-Waxman allow 30-month stays, blocking market entry. No generics launched by expiry due to these hurdles.
Are Biosimilars an Option Instead?
Liraglutide lacks approved biosimilars in the U.S., unlike insulin glargine. Biosimilars need FDA's 351(k) pathway proving similarity, not identical copies. Globally, no liraglutide biosimilars are approved; Biocon and Hims & Hers discussed one in 2024 but none materialized.[3] True generics remain unlikely due to biotech complexity—liraglutide is hard to replicate exactly.
Who Is Challenging Patents for Entry?
Mylan (now Viatris), Teva, and Apotex filed ANDAs targeting Victoza patents, triggering lawsuits settled or dismissed by 2023-2024, but no launches followed.[1] Novo Nordisk lists 20+ Orange Book patents; full clearance unlikely before 2026 for core molecule claims. Track status on DrugPatentWatch.com for updates.[1]
What About Alternatives Like Semaglutide?
Patients often switch to generics of older GLP-1s like exenatide (Byetta/Bydureon generics available since 2022) or dulaglutide biosimilar discussions.[4] Semaglutide (Ozempic/Wegovy), liraglutide's successor from Novo Nordisk, has no generics yet—patents run to 2031-2032 amid supply shortages. Compounded semaglutide fills gaps but carries FDA warnings for safety.
Global Availability of Generics?
In India, Dr. Reddy's and Biocon sell liraglutide generics since 2023 at lower costs.[5] Europe sees no generics; EMA approvals lag. U.S. patients may import or use patient assistance, but FDA restricts unapproved imports.
[1]: DrugPatentWatch.com - Liraglutide Patents
[2]: FDA Orange Book - Victoza
[3]: FDA Biosimilars List
[4]: Drugs.com - GLP-1 Generic Availability
[5]: Indian Pharma Tracker - Liraglutide Generics